Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Head Neck. 2019 May;41(5):1525-1535. doi: 10.1002/hed.25583. Epub 2018 Dec 30.
The prognostic roles of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been reported in head and neck squamous cell carcinoma (HNSCC), but their results remain controversial.
A total of 25 literatures with 28 cohorts involving 6847 HNSCC patients were included. The hazard ratio (HR) was pooled with 95% confidence interval (CI) using fixed-effects or random-effects models.
High pretreatment NLR predicted poor overall survival (OS: HR = 1.68; 95% CI = 1.39-2.03; P < .001), disease-free survival (DFS: HR = 1.76; 95% CI = 1.42-2.17; P < .001), progression-free survival (PFS: HR = 1.53; 95% CI = 1.09-2.14; P = .014), and cancer-specific survival (CSS: HR = 1.45; 95% CI = 1.23-1.71; P < .001) in HNSCC. However, the association between PLR and OS or DFS was not statistically significant.
The NLR can serve as a potential prognostic biomarker for patients with HNSCC.
中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）在头颈部鳞状细胞癌（HNSCC）中的预后作用已有报道，但结果仍存在争议。
共纳入 25 篇文献，涉及 28 个队列共 6847 例 HNSCC 患者。采用固定效应或随机效应模型，用 95%置信区间（CI）合并风险比（HR）。
高术前 NLR 预测总生存期（OS：HR=1.68；95%CI=1.39-2.03；P<0.001）、无病生存期（DFS：HR=1.76；95%CI=1.42-2.17；P<0.001）、无进展生存期（PFS：HR=1.53；95%CI=1.09-2.14；P=0.014）和癌症特异性生存期（CSS：HR=1.45；95%CI=1.23-1.71；P<0.001）不良。然而，PLR 与 OS 或 DFS 之间的关联没有统计学意义。
NLR 可作为 HNSCC 患者的潜在预后生物标志物。
